MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
1.770
-0.050
-2.75%
After Hours: 1.770 0 0.00% 16:04 12/05 EST
OPEN
1.850
PREV CLOSE
1.820
HIGH
1.890
LOW
1.760
VOLUME
26.19K
TURNOVER
--
52 WEEK HIGH
12.53
52 WEEK LOW
1.530
MARKET CAP
8.20M
P/E (TTM)
-0.2733
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at INAB last week (1124-1128)?
Weekly Report · 6d ago
IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting
Benzinga · 11/24 19:53
IN8bio Presents Promising Clinical Trial Results
TipRanks · 11/24 17:04
IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial
Reuters · 11/24 16:17
IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation
Reuters · 11/24 13:19
Weekly Report: what happened at INAB last week (1117-1121)?
Weekly Report · 11/24 10:41
Weekly Report: what happened at INAB last week (1110-1114)?
Weekly Report · 11/17 10:42
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Webull offers IN8bio Inc stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.